ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Field of Research : Endocrinology
Research Topic : Cancer Treatment
Clear All
Filter by Field of Research
Endocrinology (63)
Biochemistry and Cell Biology (3)
Biochemistry And Cell Biology Not Elsewhere Classified (2)
Bioinformatics (1)
Gene Expression (incl. Microarray and other genome-wide approaches) (1)
Oncology And Carcinogenesis (1)
Oncology and Carcinogenesis not elsewhere classified (1)
Receptors and Membrane Biology (1)
Filter by Socio-Economic Objective
Cancer and related disorders (2)
Endocrine organs and diseases (incl. diabetes) (2)
Biological sciences (1)
Cancer and Related Disorders (1)
Endocrine Organs and Diseases (excl. Diabetes) (1)
Environmental Health (1)
Health Related to Ageing (1)
Health related to ageing (1)
Filter by Funding Provider
National Health and Medical Research Council (60)
Australian Research Council (3)
Filter by Status
Closed (63)
Filter by Scheme
NHMRC Project Grants (33)
Project Grants (8)
Postgraduate Scholarships (6)
NHMRC Research Fellowships (4)
Discovery Projects (3)
Early Career Fellowships (3)
Career Development Fellowships (2)
NHMRC Postgraduate Scholarships (2)
NHMRC Development Grants (1)
Research Fellowships (1)
Filter by Country
Australia (5)
Filter by Australian State/Territory
NSW (3)
SA (2)
VIC (1)
  • Researchers (3)
  • Funded Activities (63)
  • Organisations (20)
  • Funded Activity

    Androgen Receptor Signalling In Development And Progression Of Prostate Cancer

    Funder
    National Health and Medical Research Council
    Funding Amount
    $753,420.00
    Summary
    Prostate cancer is a major health problem in Australia, being the second leading cause of cancer deaths in men. Although there have been improvements in the diagnosis and treatment of prostate cancer, there are no effective treatments for advanced (metastatic) disease that has spread to other parts of the body. Currently, the only therapy for advanced disease involves the reduction in circulating androgens such as testosterone by surgical or medical castration, i.e. androgen ablation. Because pr .... Prostate cancer is a major health problem in Australia, being the second leading cause of cancer deaths in men. Although there have been improvements in the diagnosis and treatment of prostate cancer, there are no effective treatments for advanced (metastatic) disease that has spread to other parts of the body. Currently, the only therapy for advanced disease involves the reduction in circulating androgens such as testosterone by surgical or medical castration, i.e. androgen ablation. Because prostate cells are dependent on testicular androgens for their growth and survival, surgical or medical castration results in an initial tumour regression. However, tumours inevitably develop resistance to androgen ablation therapy and regrow. In this study we aim to provide the most comprehensive analysis to date of the role of androgen signalling in the initiation and progression of prostate cancer. This will enable us to identify the most effective means of eliminating androgen-dependent prostate tumours and identify tumours with high metastatic potential. Our studies will indicate whether treatments targeting androgen signalling are a more effective strategy to inhibit prostate cancer growth while minimising undesirable side effects.
    Read more Read less
    More information
    Funded Activity

    Osteoporotic Fractures And Mortality Risk

    Funder
    National Health and Medical Research Council
    Funding Amount
    $124,325.00
    Summary
    Osteoporosis is a common problem with increased premature mortality associated with hip and even more minor fractures. The cause of increased mortality is debated although osteoporosis treatment may decrease this risk. This study will be the first to examine survival of all subjects in NSW admitted for a fracture including cause for subsequent hospitalisation and treatment taken. This study will help define the cause of the mortality and the role of anti osteoporosis treatment on outcome.
    More information
    Funded Activity

    Research Fellowship - Grant ID:358700

    Funder
    National Health and Medical Research Council
    Funding Amount
    $651,750.00
    More information
    Funded Activity

    The Ghrelin Axis As A Target For Prostate Cancer Therapy

    Funder
    National Health and Medical Research Council
    Funding Amount
    $585,497.00
    Summary
    Prostate cancer affects one in nine Australian men in their lifetime, and although there have been great advances in treatments, advanced prostate cancer remains incurable. Current treatments often lead to side effects which affect quality of life. We have found that the appetite hormone, ghrelin, stimulates prostate cancer cell growth and may be a useful target for prostate cancer therapy. We predict that targeting the ghrelin axis will prevent some of the side effects of other treatments that .... Prostate cancer affects one in nine Australian men in their lifetime, and although there have been great advances in treatments, advanced prostate cancer remains incurable. Current treatments often lead to side effects which affect quality of life. We have found that the appetite hormone, ghrelin, stimulates prostate cancer cell growth and may be a useful target for prostate cancer therapy. We predict that targeting the ghrelin axis will prevent some of the side effects of other treatments that reduce quality of life for patients.
    Read more Read less
    More information
    Funded Activity

    HEREDITARY ENDOCRINE CANCER: A MODEL BASED ON PHAEOCHROMOCYTOMA- PARAGANGLIOMA SYNDROMES

    Funder
    National Health and Medical Research Council
    Funding Amount
    $875,894.00
    Summary
    Phaeochromocytomas and paragangliomas are tumours remarkable for their very high heritability. They have a high burden of disease themselves, and their associated hereditary syndromes include risks for other malignancies. Our study will rationalize the pathological approach to diagnosing these hereditary syndromes, find new therapeutic targets for metastatic disease, and provide a template for other cancers with high heritable component.
    More information
    Funded Activity

    Prorenin And The Prorenin Receptor In Diabetic Retinopathy: Involvement Of The Wnt Pathway And Inflammation

    Funder
    National Health and Medical Research Council
    Funding Amount
    $580,042.00
    Summary
    Diabetic retinopathy is the leading cause of blindness in people of working age. The World Health Organization predicts that by 2030 more than 300 million people will have diabetes. Given the prevalence of diabetic retinopathy and the lack of effective treatments, there is an urgent need to identify the factors that contribute to its development. This project will determine the role of components of a hormonal system, prorenin and its receptor, in diabetic retinopathy and whether they are new ta .... Diabetic retinopathy is the leading cause of blindness in people of working age. The World Health Organization predicts that by 2030 more than 300 million people will have diabetes. Given the prevalence of diabetic retinopathy and the lack of effective treatments, there is an urgent need to identify the factors that contribute to its development. This project will determine the role of components of a hormonal system, prorenin and its receptor, in diabetic retinopathy and whether they are new targets for its treatment.
    Read more Read less
    More information
    Funded Activity

    Bone Resorption In Breast Cancer Metastasis

    Funder
    National Health and Medical Research Council
    Funding Amount
    $425,875.00
    Summary
    Breast Cancer has a particular preference to form cancer metastases in bone where its presence is associated with bone destruction that frequently results in significant pain and disability. Bone seems to provide a fertile soil for breast cancer cells that have moved into the blood vessels from the original cancer site in the breast. Once tumour cells have invade bone marrow spaces from the blood vessels they are able to grow and induce the normal cells of the bone marrow to destroy the surround .... Breast Cancer has a particular preference to form cancer metastases in bone where its presence is associated with bone destruction that frequently results in significant pain and disability. Bone seems to provide a fertile soil for breast cancer cells that have moved into the blood vessels from the original cancer site in the breast. Once tumour cells have invade bone marrow spaces from the blood vessels they are able to grow and induce the normal cells of the bone marrow to destroy the surrounding hard bone. This allows the tumour to grow faster. Together these processed create a vicious cycle that contributes to the serious consequences of bone metastases. In this project we will be studying mice with breast cancer to understand what makes the bone marrow such a fertile and receptive site for breast cancer metastasis. In particular, we are looking at how the normal processes of bone renewal and repair contribute to the establishment of cancer in bone. We will use the body's own bone protecting protein, called osteoprotegerin, to test how blocking bone destruction will affect the ability of cancer cells to invade and grow in bone. This study has the potential to change the way bone metastases are treated. Treatment of breast cancer could be significantly improved if the fertile soil of bone could be modified to either block the targeting of breast cancer to bone, or to inhibit its growth there.
    Read more Read less
    More information
    Funded Activity

    Research Fellowship - Grant ID:390125

    Funder
    National Health and Medical Research Council
    Funding Amount
    $739,574.00
    More information
    Funded Activity

    The Essential Role Of Androgen Receptor Signalling In Prostate Tumorigenesis

    Funder
    National Health and Medical Research Council
    Funding Amount
    $714,375.00
    Summary
    An urgent objective in prostate cancer clinical practice is to better predict disease course at diagnosis and to identify patients likely to develop metastatic (lethal) disease. We aim to identify clinically-relevant genes - gene pathways that are important in prostate cancer development and progression and which can be used to improve prediction of patient outcome. Prostate cancer management can be improved by tailoring treatments for individual patients.
    More information
    Funded Activity

    The Role Of A Protease Activated Receptor System In Prostate Cancer Bone Metastasis.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $582,204.00
    Summary
    Prostate cancer is one of the most significant health issues for men. This disease occurs because certain proteins start to function abnormally. Our focus is on a protein called PAR2, present on the surface of prostate cancer cells and bone cells, which we propose helps cancer cells to spread to bone. In our project, we aim to understand how this happens so that we can develop ways to block prostate cancer metastasis to bone.
    More information

    Showing 1-10 of 63 Funded Activites

    • 1
    • 2
    • 3
    • 4
    • 5
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback